Nevertheless, we have identified a pEGFR-positive NSCLC tumor (patient 10) with a 0.99 gefitinib-treatment score, which showed a 98% reduction in Ki67 levels upon EGFRi, thus suggesting dependency on EGFR to sustain viability (Fig. 6D). Here, MKI67 is linked to neoplasm.